Where does NXTS stock trade?

Nexentis Technologies Inc. (NXTS) is listed on NASDAQ.

What sector and industry is NXTS in?

Nexentis Technologies Inc. operates in the Industrials sector, Agricultural Chemicals industry.

What companies are similar to NXTS?

Notable peers in the same industry include NTR (Nutrien Ltd.), CF (CF Industries Holdings Inc.), MOS (Mosaic Company), ICL (ICL Group Ltd.), SMG (Scotts Miracle-Gro Company). Compare NXTS side-by-side with any of them on Quantisnow.

How can I track NXTS on Quantisnow?

Quantisnow aggregates Nexentis Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXTS to receive live email and push alerts on every new disclosure.

NXTS

NASDAQ

Nexentis Technologies Inc.

SectorIndustrialsIndustryAgricultural Chemicals

$1.92-0.21 (-9.65%)

News25/Ratings0

Price$1.92-2.78 (-59.15%)

2026-04-212026-07-24

News · 26 weeks27-29%

2026-02-012026-07-26

Mix1990d

SEC Filings11(58%)
Other8(42%)

Latest news

25 items

5dSEC
SEC Form EFFECT filed by Nexentis Technologies Inc.
EFFECT - Nexentis Technologies Inc. (0001789192) (Filer)
9dSEC
SEC Form EFFECT filed by Nexentis Technologies Inc.
EFFECT - Nexentis Technologies Inc. (0001789192) (Filer)
12dSEC
SEC Form S-1 filed by Nexentis Technologies Inc.
S-1 - Nexentis Technologies Inc. (0001789192) (Filer)
12dSEC
SEC Form POS AM filed by Nexentis Technologies Inc.
POS AM - Nexentis Technologies Inc. (0001789192) (Filer)
18dPR
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery initiative with Boltz Ness Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. ("Nexentis"), (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, has recently reported that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX Bio"), successfully completed a broad analysis of SLC transport proteins and initiated an international AI drug
26dPR
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced the signing of an Addendum to the Loan and Partnership Agreement, together with Solterra Renewable Energy Ltd. ("Solterra") and the other lenders, for its Melz solar PV project in Germany. The Addendum follows a share purchase agreement under which Solterra and its assets are being sold to Sunflower Sustainable Investments Ltd. As a result, Solterra is making early partial repayments of the loan. The Addendum, executed together with th
32dSEC
SEC Form 424B5 filed by Nexentis Technologies Inc.
424B5 - Nexentis Technologies Inc. (0001789192) (Filer)
33dSEC
Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - Nexentis Technologies Inc. (0001789192) (Filer)
33dPR
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets Neve Yarak, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has entered into an engagement with Boltz, PBC ("Boltz"), an AI research lab that focuses on biomolecular foundation models and drug discovery workflows, to accelerate the identification of novel sma
38dPR
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand and refine its small-molecule discovery capabilities. This work builds on MITOLINE®, MitoCareX's proprietary sequence analysis and alignment algorithm, which to date has been used to prepare mitochondrial SLC25 carri
40dSEC
SEC Form 424B5 filed by Nexentis Technologies Inc.
424B5 - Nexentis Technologies Inc. (0001789192) (Filer)
43dSEC
Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - Nexentis Technologies Inc. (0001789192) (Filer)
59dSEC
Nexentis Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - Nexentis Technologies Inc. (0001789192) (Filer)
68dPR
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound. This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that the Company's propr
72dSEC
SEC Form 10-Q filed by Nexentis Technologies Inc.
10-Q - Nexentis Technologies Inc. (0001789192) (Filer)
73dPR
Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
MITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit
81dPR
Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX's Algorithm Platform MITOLINE™
Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ:NXTS), ("Nexentis" or the "Company"), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™. MITOLINE™ is MitoCareX's proprietary sequence analysis and alignment algorithm designed to prepare mitochondrial carrier proteins of the SLC25 family for reliable 3D homology modeling and was designed to overcome
86dSEC
Nexentis Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
8-K - Nexentis Technologies Inc. (0001789192) (Filer)
86dSEC
SEC Form EFFECT filed by Nexentis Technologies Inc.
EFFECT - Nexentis Technologies Inc. (0001789192) (Filer)
100dSEC
SEC Form S-3 filed by Nexentis Technologies Inc.
S-3 - Nexentis Technologies Inc. (0001789192) (Filer)
110dSEC
Nexentis Technologies Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders
8-K - Nexentis Technologies Inc. (0001789192) (Filer)
116dSEC
SEC Form 10-K filed by Nexentis Technologies Inc.
10-K - Nexentis Technologies Inc. (0001789192) (Filer)
121dINSIDER
SEC Form 4 filed by Lee Eun Young
4 - Nexentis Technologies Inc. (0001789192) (Issuer)
124dINSIDER
SEC Form 3 filed by new insider Lee Eun Young
3 - Nexentis Technologies Inc. (0001789192) (Issuer)
130dSEC
Nexentis Technologies Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
8-K - Nexentis Technologies Inc. (0001789192) (Filer)

NXTS FAQ

4 questions

Where does NXTS stock trade?
Nexentis Technologies Inc. (NXTS) is listed on NASDAQ.
What sector and industry is NXTS in?
Nexentis Technologies Inc. operates in the Industrials sector, Agricultural Chemicals industry.
What companies are similar to NXTS?
Notable peers in the same industry include NTR (Nutrien Ltd.), CF (CF Industries Holdings Inc.), MOS (Mosaic Company), ICL (ICL Group Ltd.), SMG (Scotts Miracle-Gro Company). Compare NXTS side-by-side with any of them on Quantisnow.
How can I track NXTS on Quantisnow?
Quantisnow aggregates Nexentis Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXTS to receive live email and push alerts on every new disclosure.